8-K current report · filed Aug 6, 2026

BIOLIFE SOLUTIONS INC (BLFS) 8-K Current Report: August 6, 2026

Item EX-99.1Item 2.02BLFS overview

Short answer

BIOLIFE SOLUTIONS INC (BLFS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 unaudited results for quarter ended June 30, 2026.

BIOLIFE SOLUTIONS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 unaudited results for quarter ended June 30, 2026
  • Operational highlights announced August 6, 2026
  • Financial figures and management commentary contained in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $28.5M, up 21% year over year, with adjusted EBITDA $7.4M and 26% margin
  • GAAP gross margin 64%, down from 65%, while adjusted gross margin declined to 65% from 66%
  • GAAP net income $45.1M included a $42.4M non-cash tax benefit, making adjusted net income $4.2M more representative
  • Repligen agreed to acquire BioLife for approximately $1.5B enterprise value, including $11.25 cash and 0.1442 Repligen shares per BioLife share
  • Transaction expected to close in Q4 2026, subject to shareholder and regulatory approvals, after which BioLife will cease public trading

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other BIOLIFE SOLUTIONS INC 8-K filings

Get the next BLFS 8-K as it lands

Follow BLFS for push alerts, or ask the research agent what this filing means.